Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors.

Guerrero AD, Moyes JS, Cooper LJ.

Chin J Cancer. 2014 Sep;33(9):421-33. doi: 10.5732/cjc.014.10100.

2.

Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma.

Doukas J, Rolland A.

Cancer Gene Ther. 2012 Dec;19(12):811-7. doi: 10.1038/cgt.2012.69. Epub 2012 Oct 5. Review.

3.

Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer.

Elluru SR, Duong van Huyen JP, Delignat S, Kazatchkine MD, Friboulet A, Kaveri SV, Bayry J.

BMC Cancer. 2008 Jun 4;8:161. doi: 10.1186/1471-2407-8-161.

4.

Synthesis of beta(2)-microglobulin-free, disulphide-linked HLA-G5 homodimers in human placental villous cytotrophoblast cells.

Morales PJ, Pace JL, Platt JS, Langat DK, Hunt JS.

Immunology. 2007 Oct;122(2):179-88. Epub 2007 May 2.

5.

Immunosuppressive strategies that are mediated by tumor cells.

Rabinovich GA, Gabrilovich D, Sotomayor EM.

Annu Rev Immunol. 2007;25:267-96. Review.

7.
8.
9.

Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells.

Wang Z, Marincola FM, Rivoltini L, Parmiani G, Ferrone S.

J Exp Med. 1999 Jul 19;190(2):205-15.

10.

Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules.

Martayan A, Fraioli R, Giorda E, Setini A, Ciccarelli G, Delfino L, Ferrara GB, Giacomini P.

Br J Cancer. 1999 May;80(5-6):639-49.

11.

beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.

Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S.

J Clin Invest. 1998 Jun 15;101(12):2720-9.

12.

Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens.

Schadendorf D, Fichtner I, Makki A, Alijagic S, Küpper M, Mrowietz U, Henz BM.

Br J Cancer. 1996 Jul;74(2):194-9.

13.

HLA associations in the antitumor response against malignant melanoma.

Marincola FM, Shamamian P, Rivoltini L, Salgaller M, Cormier J, Restifo NP, Simonis TB, Venzon D, White DE, Parkinson DR.

J Immunother Emphasis Tumor Immunol. 1995 Nov;18(4):242-52.

14.

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.

Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA.

J Natl Cancer Inst. 1996 Jan 17;88(2):100-8.

15.

Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.

Marincola FM, Shamamian P, Simonis TB, Abati A, Hackett J, O'Dea T, Fetsch P, Yannelli J, Restifo NP, Mulé JJ, et al.

J Immunother Emphasis Tumor Immunol. 1994 Jul;16(1):13-23.

16.

Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line.

Jakobsen MK, Restifo NP, Cohen PA, Marincola FM, Cheshire LB, Linehan WM, Rosenberg SA, Alexander RB.

J Immunother Emphasis Tumor Immunol. 1995 May;17(4):222-8.

17.

Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo NP, Topalian SL, Simonis TB, Rosenberg SA, et al.

Cancer Res. 1995 Jul 15;55(14):3149-57.

Supplemental Content

Support Center